In the wake of Robert F. Kennedy Jr.’s abrupt revamp of the CDC’s Advisory Committee on Immunization Practices, details from the panel’s planned meeting next week are confirming many industry ...

The FDA’s upcoming June meeting plans to jab at a lineup of vaccines—COVID-19, RSV, flu, and even anthrax—but somehow skipped ...

Robert F. Kennedy Jr. announced a panel including vaccine skeptics, drawing criticism from public health leaders and ...

The agency’s decision to clear Moderna’s shot for use in certain younger adults is a much-needed win for a company that’s been significantly impacted by the recent changes in FDA and HHS leadership.

The FDA has approved Enflonsia (clesrovimab-cfor) for the prevention of RSV lower respiratory tract disease in neonates and ...

The Food and Drug Administration has approved a new drug from Merck designed to protect infants from respiratory syncytial ...

In a major boost for infant health, the U.S. Food and Drug Administration (FDA) has approved ENFLONSIA (clesrovimab-cfor) , a ...

GSK said on Friday the European Medicines Agency had accepted the drugmaker's application to expand the use of its ...

RayzeBio, the radiopharmaceutical unit of Bristol Myers Squibb, licensed an experimental drug and diagnostic agent for prostate cancer from Philochem AG for a $350 million upfront payment. Philochem ...

A newly approved shot could soon help protect babies from respiratory syncytial virus (RSV), the top cause of hospitalization ...

The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that’s the No. 1 cause of hospitalization in infants.

Merck & Co., Inc. (NYSE:MRK) is one of the best wide moat stocks to buy now. On June 9, Merck’s preventative antibody shot ...